Medicine
Adbry 300 mg/2 mL injection
Adbry 300 mg/2 mL injection is a prescription medicine containing Tralokinumab for subcutaneous use, marketed by LEO Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to…
Key facts
- Active ingredient (INN)
- Tralokinumab
- Brand
- Adbry
- Strength
- 300 mg/2 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 2 mL, 2 syringes of 2 mL
- Marketing authorisation holder
- LEO Pharma
- Manufacturer
- LEO Pharma
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not put ADBRY back in the refrigerator after reaching room temperature. If necessary, ADBRY may be kept at room temperature up to 30°C (86°F) for a maximum of 14 days in the original carton. Do not store above 30°C (86°F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D11 Other skin treatments
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 July 2024
- Identifiers
- RxCUI 2589378, 2589384, 2686061 +1DailyMed set ID d8020b69-3001-44e2-9b5d-5f93d9aaf6e1NDC 50222-350Application BLA761180
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / 2 mL in 1 syringe, glass | 50222-350-01 | LEO Pharma | 1 July 2024 |
| 2 syringe, glass in 1 carton / 2 mL in 1 syringe, glass | 50222-350-02 | LEO Pharma | 1 July 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tralokinumab
Clinical summary
Tralokinumab is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Tralokinumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TralokinumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Adbry prescribing information (LEO Pharma) · U.S. National Library of Medicine, DailyMed
- Adtralza: European public assessment report (EPAR) · European Medicines Agency
Need Adbry 300 mg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.